Energy Fuels Engages Constantine Karayannopoulos and Brock O’Kelley to Assist in Developing U.S. Rare Earth Element Commercial and Technical Strategies; Presenting at Mining Conference Today

Move Intensifies Energy Fuels’ Effort to Potentially Establish a Commercially Viable Rare Earth Production Capacity in the U.S. that Could Process Multiple Ore Inputs While Recycling Contained Uranium to Generate Fuel for Clean Nuclear Power Plants May 21, 2020 Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels”), the leading producer of uranium in…

Energy Fuels Enters into Agreement to Acquire Prompt Fission Neutron (PFN) Borehole Logging Technology and Equipment; Securing Control over this Critical Technology for U.S. ISR Uranium Production

LAKEWOOD, CO, May 6, 2020 /CNW/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels”), the leading producer of uranium in the United States, is pleased to announce that it has entered into an agreement to acquire from GeoInstruments Logging LLC (“GIL”) all of its Prompt Fission Neutron (“PFN”) technology and equipment, including all of its related…

CURE Pharmaceutical Expands Cannabis Extraction Patents, Adding Support for CBG for Therapeutic Solutions

Equipment manufacturers, cannabis processors and drug developers can license CURE’s patented methods for optimal extraction of cannabinoids LOS ANGELES, April 21, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the issuance of two U.S. Patents: No. 10,639,339 and 10,624,940. These patents represent an expansion of CURE’s existing “product by…

Energy Fuels Announces 2019 Results

LAKEWOOD, CO, March 16, 2020 /CNW/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”) today reported its financial results for the year ended December 31, 2019. The Company’s annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission (“SEC“) and may be viewed on the Electronic Document Gathering…

CURE Pharmaceutical Secures Chinese Patent on its Oral Thin Films to Treat Erectile Dysfunction

GlobeNewswire•March 17, 2020 ED Drug Market Expected to Reach US$6.5B by 2025 OXNARD, Calif., March 17, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of Chinese Patent No. ZL201480039313.6. The new patent covers the loading of high amounts of active drug on an oral thin film using…

CURE Pharmaceutical Licenses Cannabis Extraction Patents to Vanguard Scientific

GlobeNewswire•February 12, 2020 Vanguard Scientific builds customer trust with CUREinside™ patented methods LOS ANGELES, Feb. 12, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced a licensing and collaboration agreement with Vanguard Scientific Systems, Inc., a premier provider of equipment, systems and performance solutions servicing the botanical extraction…

Energy Fuels Applauds President Trump’s 10-Year, $1.5 Billion Plan to Establish U.S. Uranium Reserve

PR Newswire•February 11, 2020 LAKEWOOD, CO, Feb. 11, 2020 /PRNewswire/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”), a leading uranium producer in the U.S., applauds President Trump for yesterday announcing a budget that seeks $150 million per year over the next 10 years (totaling $1.5 billion over that…

CURE Pharmaceutical Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery

GlobeNewswire•February 5, 2020 CURE debuts “CUREinside” quality mark on the packaging of ReLeaf Europe’s sublingual tinctures and new topical cream product lines OXNARD, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, announced today that it has signed an exclusive licensing agreement with ReLeaf Europe, one of…

CURE Pharmaceutical Names Canopy Rivers’ Chairman, John K. Bell, To Board of Directors

Industry veteran brings 40 year of experience to support CURE’s rapid growth OXNARD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it has named John K. Bell, FCA, FCPA, ICD.D to its board of directors. Bell brings more than 40 years of experience…